Clinical trials
Phase 3 Multiple Myeloma trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
84 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 2 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 6 |
| 2024 | 7 |
| 2025 | 1 |
| 2026 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Active, not recruiting | 17 |
| Recruiting | 17 |
| Terminated | 3 |
| Not yet recruiting | 2 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Janssen Research & Development, LLC | 13 |
| Celgene | 10 |
| Amgen | 6 |
| Bristol-Myers Squibb | 6 |
| AbbVie | 5 |
| Pfizer | 4 |
| Takeda | 4 |
| AstraZeneca | 3 |
| Millennium Pharmaceuticals, Inc. | 3 |
| NCIC Clinical Trials Group | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Myeloma | 84 |
| Recurrence | 16 |
| Neoplasms, Plasma Cell | 11 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 |
| Lymphoma | 5 |
| Neoplasms | 5 |
| Burkitt Lymphoma | 4 |
| Lymphoma, Non-Hodgkin | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 |
| Blast Crisis | 3 |
Trials
Showing 1 to 25 of 84. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.